OR WAIT null SECS
July 13, 2022
Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.
July 08, 2022
Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.
VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.
NRG Therapeutics and Domainex aim to develop novel small-molecule drugs to treat neurodegenerative disorders, such as Parkinson’s disease.
LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.
June 30, 2022
Ipsen will acquire Epizyme, who recently had their lead medicine Tazverik (tazemetostat) approved by FDA for treatment of relapsed or refractory follicular lymphoma.
Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.
June 29, 2022
The European Commission has approved Cosentyx for the treatment of various childhood arthritic conditions.
The European Commission has approved Xenpozyme as the first treatment for ASMD.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.